Chemotherapeutic potential of phosphodiesterase inhibitors

Current Opinion in Chemical Biology

Volumn 2, Issue 4, 1998, Pages 472-481

  Perry, Martin J ^a   Higgs, Gerald A ^a  

^a UCB PHARMA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; CYCLIC GMP; ISOENZYME; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR;

CHEMISTRY; CLINICAL TRIAL; GENETICS; HUMAN; METABOLISM; REVIEW;

CLINICAL TRIALS; CYCLIC AMP; CYCLIC GMP; HUMANS; ISOENZYMES; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES;

EID: 0032134209     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1367-5931(98)80123-3     Document Type: Article

References (70)

1. Houslay MD, Milligan G: Tailoring cAMP singalling responses through isoform multiplicity. Trends Biochem Sci 1997, 22:217-224. An excellent, detailed review of the isoform multiplicity utilized in mammalian cyclic nucleotide signalling.
2. Scott JD: Dissection of protein kinase and phosphatase targeting intgeractions. Soc Gen Physiol Ser 1997, 52:227-239.
3. Beavo JA: Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 1995, 75:725-748.
4. Ashida S, Sakuma K: Demonstration of functional compartments of cyclic AMP in rat platelets by the use of phosphodiesterase inhibitors. Adv Second Messenger Phosphoprotein Res 1992, 25:229-239.
5. MacFarland RT, Zelus BD, Beavo JA: High concentrations of a cGMP-stimulated phosphodiesterase mediate ANP-induced decreases in cAMP and steroidogenesis in adrenal glomerulosa cells. J Biol Chem 1991, 266:136-142.
6. Rybalkin SD, Beavo JA: Multiplicity within cyclic nucleotide phosphodiesterases. Biochem Soc Trans 1996, 24:10005-10009.
7. Yan C, Zhao AZ, Bentley JK, Beavo JA: The calmodulin dependent phosphodiesterase gene PDE1C encodes several functionally different splice variants in a tissue specific manner. J Biol Chem 1996, 271:25699-25706.
8. Sonnenburg WK, Rybalkin SD, Bromfeldt KE, Kwak KS, Ryalkina AG, Beavo JA: Identification, quantitation, and cellular location of PDE1 calmodulin stimulated cyclic nucleotide phosphodiesterase. Methods Enzymol 1998, 14:3-19.
9. Demoliou-Mason CD: Cyclic nucleotide phosphodiesterase inhibitors. Exp Opin Ther Patents 1995, 5:417-430.
10. Vemulapalli S, Watkins RW, Chintala M: Anti-platelet and antiproliferative effects of SCH 51866 a novel type I and V phosphodiesterase inhibitor. Cardiovasc Pharmacol 1996, 28:862-869.
11. Sybertz E, Czarniecki M: Inhibitors of PDE1 and PDE5 cGMP phosphodiesterases. Exp Opin Ther Patents 1997, 7:631-639. Comprehensive analysis of the patent literature on inhibitors of phosphodiesterase 1 and 5.
12. Rosman GJ, Martins TJ, Sonnenburg WK, Beavo JA, Fergusen K, Loughney K: Isolation and characterisation of human cDNAs encoding a cGMP-stimulatd 3′, 5′-cyclic nucleotide phosphodieasterase. Gene 1997, 191:89-95.
13. Michie AM, Lobban M, Muller T, Harnett MM, Houslay MD: Rapid regulation of PDE2 and PDE4 cyclic AMP phosphodiesterase activity following ligation of the T cell antigen receptor on thymocytes. Cell Signal 1996, 8:97-110.
14. Dickinson NT, Jang EK, Haslam RJ: Activation of cGMP stimulated phosphodiesterase by nitroprusside limits cAMP accumulation in human platelets - effects on platelet aggregation. Biochem J 1997, 323:371-377.
15. Porzumeit T, Nenstiel P, Muller A: Isoenzyme selective inhibition of cGMP-stimulated cyclic nucleotide phosphodiesterases by erythro-9-(2-hydroxy-3-nonyl)adenine. Cell Signal 1995, 7:733-778.
16. Rivertbastide M, Vandecasteele G, Hatem S, Verde I, Benardeau A, Mercadier JJ, Fischmeister R: cGMP stimulated cyclic phosphodieasterase regulates the basal calcium current in human atrial myocytes. J Clin Invest 1997, 99:2710-2718.
17. Leroy M-J, Degerman E, Taira M, Murata T, Wang LH, Movesian MA, Meacci E, Manganiello VL: Characterisation of two recombinant PDE3 cGMP-inhibited cyclic nucleotide phosphodiesterase isoforms, RcGIPI and Hc GIP2 expressed in NIH 3006 murine fibroblasts and SF9 insect cells. Biochemistry 1996, 35:10194-10202.
18. Degerman E, Belfrage P, Manganiello VC: Structure, localisation and regulation of cGMP-inhibited phosphodiesterase (PDE3). J Biol Chem 1997, 272:6823-6826. This reviews the tissue-specific expression, subcellular localisation and structure of phosphodiesterase 3 isoenzymes.
19. Degerman E, Landstrom TR, Wykander J, Holst LS, Admnad F, Belfrage P, Manganiello V: Phosphorylation and activation of hormane sensitive adipocyte phosphodiesterase type 3B. Methods 1998, 14:43-53.
20. Sheth SB, Chagantk K, Bastepe M, Ajuria J, Brennan K, Biradavolo R, Colman RW: Cyclic AMP phosphodiesterases in human lymphocytes. Br J Haematol 1997, 99:784-789.
21. Komas N, Movesian M, Kedev S, Degerman E, Belfrage P, Manganiello VC: cGMP inhibited phosphodiesterases (PDE3). In Handbook of Immunopharmacology: Phospodiesterase Inhibitors. Edited by Schudt C, Dent G, Rabe KF. London: Acadamic Press; 1996:89-109.
22. Packer M, Carver JR, Rodehoffer RJ, Ivanhoe RJ, Dibianco R, Veldis SM, Hendrix GH, Bommer WJ, Elkayan U, Kukin ML: Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. New Engl J Med 1991, 325:1468-1475.
23. Arnold M: The role of phosphodiesterase inhibitors in heart failure. Pharmacol Ther 1993, 57:161-170.
24. Matthew L, Katz SD: Calcium agents in heart failure. Drugs Aging 1998, 12:191-204.
25. Luben J, Just H, Hjalmarrsson AC, LaFramboise D, Remme WJ, Heinrich-Nols J, Dumont JM, Seed P: Effect of pimobendan on exercise capacity in patients with heart failure: main results from pimobendan in congestive heart failure (PICO) trial. Heart 1996, 76:223-231.
26. + T-lymphocytes role in regulating proliferation an dhte biosynthesis of interleukin -2. Br J Pharmacol 1996, 118:1945-1958.
27. Schult C, Tenor H, Hatzelmann A: PDE isoenzymes as targets for anti-asthma drugs. Eur Respir J 1995, 8:1179-1183.
28. Hughes B, Owens RJ, Perry MJ, Warrellow G, Allen R: PDE4 Inhibitors: The use of molecular cloning in the design and development of novel drugs. Drug Discov Today 1997, 2:89-101.
29. Nemoz G, Prigent AF, Moueqqit M, Fougles S, Macovschi O, Pacheco H: Selective inhibitors of one of the cyclic cAMP phosphodiesterases from rat brain by the neurotropic compound rolipram. Biochem Pharmacol 1985, 34:2997-3000.
30. Palfreyman MN, Souness JE: Phosphodiesterase Type IV Inhibitor. Prog Med Chem 1996, 33:1-52.
31. Torphy TJ: Phosphodiestease isoenzymes - molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 1998, 157:351-370. A comprehensive review of the biology of phosphodiesterase 4 that underpins the potential utility of selective inhibitors in the treatment of asthma.
32. Teixeira MM, Gristood RW, Cooper N, Hellewell PG: hosphodiesterase PDE4 inhibitors anti-inflammatory drugs of the future? Trends Pharmacol Sci 1997, 18:164-170. A concise overview of the preclinical pharmacology of phosphodiesterase inhibitors.
33. Hebenstriet GF, Fellerer K, Fichte K, Fischer G, Geyer N, Meya W, Sastre-y-Hernandez M, Schony W, Schratzer M, Soukop W: Rolipram in major depressiive disorders. Pharmacopsychiatry 1989, 22:156-160.
34. Saletu B, Anderer P, Fischhof PK, Lorenz H, Barousch R, Bohmer F: EEG mapping and psychopharmacology with denbufylline in STAT and MID. Biol Psychiatry 1992, 32:668-681.
35. Karlsson JA, Aldous D: Phosphodiesterase 4 inhibitors for the bull; treatment of asthma. Exp Opin Ther Patents 1997, 7:989-1003. A review of selective and nonselective inhibitors of phosphodiesterase. Analysis of the various chemical strategies is followed.
36. Souness JE, Rao S: Proposal for pharmacologically distruct conformers of the PDE4 cyclic AMP phosphodiesterases. Cell Signal 1 997, 9:227-236. This evaluates the biological, and in particular the functional, evidence for the existence of distinct conformational states of phosphodiesterase.
37. Duplantier AJ, Biggers MS, Chambers RJ, Cheng JB, Cooper K, Damon DB, Eggler JF, Kraus KG, Marfat A, Masamune H et al.: Biarylcarboxylic acids and -amides: inhibition of phosphodiesterase type IV versus [3H] rolipram binding activity and their relationship to emetic behaviour in the ferret. J Med Chem 1996, 39:120-125.
38. Owens RJ, Catterall C, Batty D, Jappy J, Ruseell A, Smith B, O'Connell J, Perry MJ: Human phosphodiesterase 4A: characterisation of full length and truncated enzymes expressed in cos cells. Biochem J 1997, 326:53-60. This paper covers the identification of the influence of the amino-terminal domain of phosphodiesterase 4A on the kinetics of rolipram inhibition.
39. Jacobitz S, McLaughlin HM, Livi GP, Burman M, Torphy TJ: Mapping the functional domains of human recombinant phosphoridesterase 4A: structural requirements for catalytic activity. Mol Pharmacol 1996, 50:891-899.
40. Rocque WJ, Tian G, Wissman JS, Holmes WD, Zajac Thompson I, Willard DH, Patel IR, Wisely GB, Clay WC et al.: Human recombinant phosphodiesterase 4B2B binds R-rolipram at a single site with two affinities. Biochemistry 1997, 36:14250-14261. A detailed mechanistic study of phosphodiesterase (PDE) 4B inhibition using purified enzyme. It is the only detailed kinetic analysis of a PDE isoenzyme yet reported and identifies the role of the amino-terminal domain of PDE4B in determining inhibitor sensitivity.
41. Barnette MS, Christensen SB, Essayen DM, Groos M, Prabhakar U, Rush J A, Kagey-Sobotka A, Torphy T:Ariflo a potent and selective second generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions. J Petrol 1997, 284:420-426.
42. Perry MJ, O'Connell J, Walker C, Crabbe T, Baldock D, Russell A, Lomb S, Hoang Z, Howat D, Allen R, Meriman M, Walls J, Daniel T, Hughes B, Laliberte F, Higgs GA, Owens RJ: CDP 840 a novel inhibtor and phosphodiesterase type 4. Cell Biochem Biophys 1998, 29:113-132.
43. Harbinson PL, Macleod D, Hawksworth R, Otoob J, Sullican PJ, Heath P, Kilfather S, Page CP, Costello J, Holgate ST, Lee TH: The effect of a novel orally active selective PDE4 isoenzyme inhibitor (CDP 840) on allergen induced responses in asthmatic subjects. Eur Respir J 1997, 10:1008-1014. Although numerous phosphodiesterase 4 inhibitors have entered clinical trials for asthma, this is the only report indicating efficacy in the absence of adverse events.
44. Morrison JF, Walsh CT: The behaviour and significance of slow binding enzyme inhibitors. Adv Enzymol Rel Areas 1988, 61:201-301.
45. Pettipher ER, Labasi JM, Salter ED, Stam EJ, Cheng JB, Griffiths RJ: Regulation of tumour necrosis factor production by adrenal hormones in vivo. Insights into the anti-inflammatory activity of rolipram. Br J Pharmacol 1996, 117:1530-1534.
46. Souness JE, Carter CM, Diocee BK, Hassal GA, Wood LJ, Turner NC: Characterisation of guinea-pig eosnophil phosphodiesterase activity. Biochem Pharmacol 1991, 42:937-943.
47. Jonker GJ, Tijhus GJ, de Monchyjar, JGR: RP73401 (a phosphodiesterase inhibitor) does not prevent allergen induced broncho-constriction during the early phase reaction in asthmatics. Eur Respir J 1996, 9(suppl):2382.
48. Ukena D, Rentz K, Reiber C, Sybrecht GW: Effects of the mixed phosphodiesterase III/IV inhibitor zardaverine on airway function in patients with chronic airflow obstruction. Respir Med 1995, 89:441-444.
49. irby DS, Weiner ES: Type IV phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J Invest Dermatol 1996, 107:51-56.
50. Rosin LJ, Duell EA, Voorhees JJ: Papaverine and Ro20-1724 inhibit cyclic nucleotide phosphodiesterase activity and increase cyclic AMP levels in Psoriatic Epidermis in vitro. J Invest Dematol 1978, 78:154-156.
51. Turko IV, Francis SH, Corbin JD: Hydropathic analysis and mutagenesis of the catalytic domain of the cGMP binding cGMP specific phosphodiesterase (PDE5) - cGMP versus cAMP substrate selectivity. Biochemistry 1998, 37:4200-4205. The mechanism of discrimination between cGMP and cAMP in the catalytic site of phosphodiesterase 5 is investigated. Amino acid residues critical for cGMP binding are identified.
52. Turko IV, Francis SH, Corbin JD: Potential roles of covered amino acids in the catalytic domain of the cGMP-binding cGMP specific phosphidesterase (PDE5). J Biol Chem 1998, 273:6460-6466. This paper identifies amino acids important for catalysis of cGMP by phosphodiesterase 5. Key residues for binding zaprinast differed from those invoved in binding substrate.
53. Turko IV, Francis SH, Corbin JD: Binding of cGMP to both allosteric sites of cGMP binding cGMP specific phodphodisterase (PDE5) is required for its phosphorylation. Biochem J 1998, 329:505-510. This paper demonstrates that cGMP binding to allosteric sites of PDE5 does not alter catalysis but regulates phosphorylation of this isoenzyme.
54. Poison JB, Strada SJ: Cyclic nucleotide phosphodiesterases and vascular smooth muscle. Annu Rev Pharmacol Toxicol 1996, 36:403-427.
55. Terrett N, Bell A, Brown D, Ellis P: A potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction. Bioorg Med Chem Lett 1996, 6:1819-1824.
56. Dumaitre B, Dodic N: Synthesis and cGMP phosphodiesterase inhibitory activity of a series of 6-phenylpyrazolo (3,4-d) -pyrimidones. J Med Chem 1 996, 39:1635-1644.
57. Saeki T, Adachi H, Takase Y, Souda S, Saito I: A selective type V phosphodiesterase inhibitor, E4021, dilates porcine large coronary artery. J Pharmacol Exp Ther 1995, 272:825-831.
58. Saeki T, Takese Y: Phosphodiesterase 5 inhibitors in development for cardiovascular therapy. Exp Opin Invest Drugs 1996, 5:1477-1486.
59. Guiliano F, Rampin O, Benoit G, Jardin A: The peripheral pharmacology of erection. Prog Urol 1997, 7:24033.
60. Andersson KE, Stief CG: Neurotransmission and the contraction and relaxation of penile erectile tissues. World J Urol 1997, 15:14-20.
61. Boolell M, Allen MJ, Ballard SA, Gepi-Altee S, Muirhead GJ, Naylor AM, Osterloh IH, Gingell C: Sildenafil: an orally active type 5 cyclic CMP specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction, Int J Impot Res 1996, 8:47-52.
62. Jeremy JY, Ballard SA, Naylor AM, Miller MAW, Angelini GD: Effects of sildenafil, a type 5 cGMP phosphodiesterase inhibitor and papaverine on cyclic GMP and cylic AMP levels in the rabbit corpus cavernosum in vitro. Br J Urol 1997, 79:958-963.
63. Artemyev NO, Arshaveky VY, Cote RH: Photoreceptor phosphodiesterase-interaction of inhibitory gamma subunit and cyclic GMP with specific binding sites in catalytic subunits. Br J Urol 1997, 79:958-963.
64. Sybertz EJ, Czarniecki M, Ahn H: cGMP phosphodiesterase inhibition: a new mechanism for discovery of therapeutic agents. Curr Pharm Design 1995, 1:373-390.
65. Ichimura M, Kase H: A new cyclic nucleotide phosphodiesterase isoenzyme expressed in T-lymphocyte cell lines. Biochem Biophys Res Comm 1993, 193:985-9990.
66. Han P, Zhu X, Michaeli T: Alternative splicing of the high affinity cAMP specific phosphodiesterase (PDE 7A) MRNA in human skeletal muscle and heart. J Biol Chem 1997, 272:16152-16157. Demonstration that previously isolated HCP1 cDNA encoded the full length phosphodiesterase 7A1 (PDE7A1) protein. Identification that phosphodiesterase 7A2 (PDE7A2) is a novel 5′ splice variant of PDE7A.
67. Bloom TJ, Beavo JA: Identification and tissue-specific expression of PDE 7 phosphodiesterase splic variants. Proc Natl Acad Sci USA 1996, 93:14188-92.
68. Fisher DA, Smith JF, Pillar JS, Denis SH, Cheng JB: Isolation and characterisation of PDE 8A, a novel human cAMP specific phosphodiesterase. Biochem Biophys Res Commun 1998, 246:570-577. This paper descibes the identification of a novel phosphodiesterase (PDE) family, PDE8.
69. Fisher DA, Smith, JF, Pillar JS, Denis SH, Cheng JB: Isolation and characterisation of PDE 9A, a novel human cGMP-specific phosphodiesterase. J Biol Chem 1998, 273:15559-15564. This paper describes the identification of a novel phosphodiesterase (PDE) family, PDE9.
70. Soderling SH, Bayuga SJ, Beavo JA: Identification and characterisation of a novel family of cyclic nucleotide phosphodiesterases. J Biol Chem 1998, 273:15553-15558. This paper describes the identification of a novel phosphodiesterase (PDE) family, PDE9.